NASDAQ:LYRA
Lyra Therapeutics Inc. Stock News
$0.383
+0.0154 (+4.19%)
At Close: May 17, 2024
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2021 Results - Earnings Call Transcript
08:41pm, Monday, 09'th Aug 2021
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2021 Results - Earnings Call Transcript
Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
07:00am, Monday, 12'th Jul 2021
WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, susta
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
07:00am, Wednesday, 30'th Jun 2021
-- Results Support 505(b)(2) NDA Pathway for LYR-210
Lyra Therapeutics Stock Is Trading Higher After Positive FDA Meeting Outcome For Rhinosinusitis Program
05:48am, Wednesday, 09'th Jun 2021
Lyra Therapeutics Inc (NASDAQ: LYRA) announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the FDA for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis (C
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local de
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q1 2021 Results - Earnings Call Transcript
09:51pm, Tuesday, 11'th May 2021
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q1 2021 Results - Earnings Call Transcript
Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
03:36pm, Sunday, 11'th Apr 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q4 2020 Results - Earnings Call Transcript
08:50pm, Tuesday, 09'th Mar 2021
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q4 2020 Results - Earnings Call Transcript
Why Earnings Season Could Be Great for Lyra Therapeutics (LYRA)
09:52am, Monday, 01'st Mar 2021
Lyra Therapeutics (LYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.
6 Reasons Not To Invest In Harvest Capital (NASDAQ:HCAP)
10:07am, Friday, 16'th Oct 2020
Harvest Capital's portfolio is in shambles, as its portfolio companies alternate in and out of default, receiving cash injections, refinancing and credit amendments.
NHS 111 call centre was unsafe, says worker who nearly died from Covid
05:00am, Monday, 12'th Oct 2020
Stephen Poore, who spent 42 days on ventilator, says there was no social distancing at Ashford office
Nurses barred from NHS 111 Covid clinical division after 60% of calls unsafe
06:02pm, Thursday, 01'st Oct 2020
Concern grows over 111 guidance after audit of clinical calls handled by nurses, paramedics and physios
Reviewing Lyra Therapeutics (NASDAQ:LYRA) & Antares Pharma (NASDAQ:ATRS)
01:50am, Tuesday, 11'th Aug 2020
Lyra Therapeutics (NASDAQ:LYRA) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of
